Recruiting
Chronic lymphocytic leukaemia+2
RecruitingInvestigationalNo placebo
Safety Study of Sonrotoclax and Zanubrutinib for Patients with Untreated Chronic Lymphocytic Leukemia
InvestigationalNo placebo
- Disease:Chronic lymphocytic leukaemiaMantle cell lymphoma recurrent+1
- Substances:ZanubrutinibN-[4-({[(1R,4R)-4-Hydroxy-4-Methylcyclohexyl]Methyl}Amino)-3- Nitrobenzene-1-Sulfonyl]-4-(2-{(2S)-2-[2-(Propan-2-Yl)Phenyl]Pyrrolidin1-Yl}-7-Azaspiro[3.5]Nonan-7-Yl)-2-[(1H-Pyrrolo[2,3-B]Pyridin-5- Yl)Oxy]Benzamide
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:Zanubrutinib
- Sponsor:BeOne Medicines AG










